AU2021266154A1 - 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases - Google Patents

5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases Download PDF

Info

Publication number
AU2021266154A1
AU2021266154A1 AU2021266154A AU2021266154A AU2021266154A1 AU 2021266154 A1 AU2021266154 A1 AU 2021266154A1 AU 2021266154 A AU2021266154 A AU 2021266154A AU 2021266154 A AU2021266154 A AU 2021266154A AU 2021266154 A1 AU2021266154 A1 AU 2021266154A1
Authority
AU
Australia
Prior art keywords
compound
quinoline
oxo
hydroxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021266154A
Other languages
English (en)
Inventor
David Malcolm Crowe
Martin Hans JOHANSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aqilion AB
Original Assignee
Aqilion AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aqilion AB filed Critical Aqilion AB
Publication of AU2021266154A1 publication Critical patent/AU2021266154A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2021266154A 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases Pending AU2021266154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2006390.5A GB202006390D0 (en) 2020-04-30 2020-04-30 Novel treatments
GB2006390.5 2020-04-30
PCT/EP2021/061464 WO2021219881A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
AU2021266154A1 true AU2021266154A1 (en) 2023-01-05

Family

ID=71080611

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021266154A Pending AU2021266154A1 (en) 2020-04-30 2021-04-30 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases
AU2021262514A Pending AU2021262514A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021262514A Pending AU2021262514A1 (en) 2020-04-30 2021-04-30 Treatments of inflammatory bowel disease

Country Status (9)

Country Link
US (2) US20230167064A1 (enExample)
EP (2) EP4142725A1 (enExample)
JP (2) JP2023524519A (enExample)
KR (2) KR20230018386A (enExample)
CN (2) CN115916200A (enExample)
AU (2) AU2021266154A1 (enExample)
CA (2) CA3177000A1 (enExample)
GB (2) GB202006390D0 (enExample)
WO (2) WO2021219879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
JP2023527782A (ja) * 2020-05-21 2023-06-30 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びその使用
CN115120727B (zh) * 2022-06-16 2024-02-23 甘肃农业大学 S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
AU2011274496B2 (en) * 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
JP5934202B2 (ja) * 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
KR20130065728A (ko) * 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
US9200046B2 (en) * 2011-06-29 2015-12-01 Cornell University Reporter system for high throughput screening of compounds and uses thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Also Published As

Publication number Publication date
WO2021219881A1 (en) 2021-11-04
US20230167064A1 (en) 2023-06-01
KR20230018386A (ko) 2023-02-07
CN115768429B (zh) 2024-02-09
GB202006390D0 (en) 2020-06-17
CN115916200A (zh) 2023-04-04
AU2021262514A1 (en) 2023-01-05
KR20230024892A (ko) 2023-02-21
EP4142725A1 (en) 2023-03-08
GB2605894A (en) 2022-10-19
CN115768429A (zh) 2023-03-07
JP2023524519A (ja) 2023-06-12
WO2021219879A1 (en) 2021-11-04
JP2023524518A (ja) 2023-06-12
EP4142724A1 (en) 2023-03-08
US20230202982A1 (en) 2023-06-29
GB202207709D0 (en) 2022-07-06
GB2605894B (en) 2023-06-14
JP7702427B2 (ja) 2025-07-03
CA3177000A1 (en) 2021-11-04
CA3176994A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
ES2389889T3 (es) Formulación de rasagilina de liberación retardada
WO2021219881A1 (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases
US10377757B2 (en) Crystal form of JAK inhibitor and preparation method thereof
EP2603509A1 (en) Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
US10548905B2 (en) Amorphous onapristone compositions and methods of making the same
WO2003082806A1 (en) Venlafaxine base
WO2012114325A1 (en) Polymorphs of asenapine maleate
WO2017109772A1 (en) Amorphous form of selexipag
CN117736193B (zh) 一种氘代稠环化合物及其制备方法与用途
EP3880683B1 (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
US20100112051A1 (en) Tianeptine sulfate salt forms and methods of making and using the same
US20230303542A1 (en) Solid forms of a parp14 inhibitor
CN102770416A (zh) 美他沙酮共晶体
WO2020187674A1 (en) Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
US8476307B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
HK40056406B (en) Monohydrate potassium salt of a thienopyridone derivative and its preparation process
US20050176798A1 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof